NCI Definition: An astrocytic tumor of uncertain relation to pilocytic astrocytoma. It occurs predominantly in infants and young children. It is characterized by a monomorphic architectural pattern, usually associated with the absence of Rosenthal fibers and eosinophilic granular bodies. The clinical course is usually aggressive. 
Pilomyxoid astrocytomas most frequently harbor alterations in BRAF, KIAA1549, NF1, FGFR1, and ZNF703 .
KIAA1549-BRAF Fusion, KIAA1549 Fusion, BRAF-KIAA1549 Fusion, BRAF V600E, and BRAF Mutation are the most common alterations in pilomyxoid astrocytoma .
There are 2 clinical trials for pilomyxoid astrocytoma, of which 2 are open and 0 are completed or closed. Of the trials that contain pilomyxoid astrocytoma as an inclusion criterion, 2 are phase 1/phase 2 (2 open).
Bevacizumab, carboplatin, and cetuximab are the most common interventions in pilomyxoid astrocytoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.